You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長春高新(000661.SZ):利斯的明透皮貼劑的境外生產藥品註冊上市許可申請已獲受理

格隆匯4月12日丨長春高新(000661.SZ)公佈,2022年4月12日,金賽藥業接到綠葉製藥通知,其開發的中樞神經治療領域產品利斯的明透皮貼劑(一週兩次)的境外生產藥品註冊上市許可申請已獲中國國家藥品監督管理局藥品審評中心受理,用於治療輕、中度阿爾茨海默病的症狀。

此次獲批受理的利斯的明透皮貼劑(一週兩次)是目前市場上已有的利斯的明貼劑(單日貼)劑型的改良貼劑,該產品及其製劑工藝已獲得多項國際專利。相比市售的利斯的明透皮貼劑(單日貼)在減少給藥頻率、簡化用藥管理的同時,能夠更加有效地提高患者用藥依從性。

此前披露,公司控股子公司——長春金賽藥業有限責任公司(“金賽藥業”)經綠葉製藥集團有限公司(“綠葉製藥”)的全資附屬公司——Luye Pharma Switzerland AG (“綠葉瑞士”)授予取得了利斯的明透皮貼劑在中國(不含香港、澳門、台灣地區)進口、銷售、推廣、營銷與使用授權產品的獨家不可轉讓的、可分許可的永久商業化權利。該事項已由公司於2021年12月21日召開的第十屆董事會第九次會議審議通過並正式推進。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account